MGNX - マクロジェニクス (MacroGenics Inc.) マクロジェニクス

 MGNXのチャート


 MGNXの企業情報

symbol MGNx
会社名 MacroGenics Inc (マクロジェニクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 マクロジェニックス(MacroGenics Inc.)は臨床段階のバイオ医薬品会社である。同社は癌と自己免疫疾患及び感染症の治療用のモノクローナル抗体ベースの治療薬の発見と開発を中心とする。同社は抗体ベースの技術プラットフォームを使用して、また他の生物医薬品企業と協力して治療薬候補を開発する。ヒトの臨床試験では、主に技術プラットフォームを使用して作成された各タイプの癌の治療薬として製品候補のパイプラインがある。臨床製品候補であるmargetuximabは、Fc最適化プラットフォームを使用して強化された。同社はまた、免疫調節タンパク質のB7ファミリーのタンパク質であるB7-H3を標的とするいくつかの製品候補を開発している。同社の製品候補には、enoblituzumabおよびMGD009、MGC018、MGD006(フロテツズマブ)、MGD007、MGD011(duvortuxizumab)、PF-06671008およびMGD010も含まれる。   マクロジェニクスは米国のバイオ医薬品企業。癌や自己免疫疾患の治療薬としてモノクロ―ナル抗体の開発を手掛ける。乳癌、食道癌、膀胱癌の治療薬Margetuximab、黒色腫、膠芽細胞腫、前立腺癌、乳癌などの治療薬MGA271や、血液癌の治療薬MGD006、結腸直腸癌の治療薬MGD007、1型糖尿病治療薬Teplizumabの開発を行う。   MacroGenics is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.
本社所在地 9704 Medical Center Drive Rockville MD 20850 USA
代表者氏名 Paulo F. Costa パウロF.コスタ
代表者役職名 Independent Chairman of the Board
電話番号 +1 301-251-5172
設立年月日 36739
市場名 NASDAQ National Market System
ipoyear 2013年
従業員数 330人
url www.macrogenics.com
nasdaq_url https://www.nasdaq.com/symbol/mgnx
adr_tso
EBITDA EBITDA(百万ドル) -31.49200
終値(lastsale) 20.19
時価総額(marketcap) 852772803.15
時価総額 時価総額(百万ドル) 791.52860
売上高 売上高(百万ドル) 177.55100
企業価値(EV) 企業価値(EV)(百万ドル) 490.63460
当期純利益 当期純利益(百万ドル) -34.09600
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 MacroGenics Inc revenues increased from $3.7M to $23.5M. Net loss increased 18% to $92.8M. Revenues reflect Revenue from collaborative agreements increase from $2.4M to $23.1M. Higher net loss reflects Research&development-Bal Val increase of 47% to $94M (expense) General and administrative - Balancing v increase of 34% to $16.5M (expense).

 MGNXのテクニカル分析


 MGNXのニュース

   Hedge Funds Have Never Been This Bullish On MacroGenics Inc (MGNX)  2021/07/06 14:20:46 Insider Monkey
   H.C. Wainwright Stick to Their Buy Rating for MacroGenics By Investing.com  2021/06/28 10:27:02 Investing.com
H.C. Wainwright Stick to Their Buy Rating for MacroGenics
   Zai Lab and Macrogenics partner in $1.5B cancer deal  2021/06/22 18:10:13 BioWorld
Zai Lab Ltd. and Macrogenics Inc. have announced a collaboration and license agreement involving up to four immuno-oncology molecules in a deal potentially worth upward of $1.5 billion. The deal makes sense as both are upcoming companies at around the same stage in development making progress in oncology with first products recently approved by regulators.
   NASDAQ:MGNX Long Term Investor Notice: Investigation of Potential Wrongdoing at MacroGenics, Inc.  2021/06/22 16:00:00 SBWire
An investigation on behalf of current long term investors in MacroGenics, Inc. (NASDAQ:MGNX) shares over possible breaches of fiduciary duty by certain officers and directors was announced. San Diego, CA -- ( SBWIRE ) -- 06/22/2021 -- Certain directors of MacroGenics, Inc. are under investigation concerning potential breaches of fiduciary duties. Investors who are current long term investors in MacroGenics, Inc. (NASDAQ: MGNX) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for investors in NASDAQ: MGNX stocks follows a lawsuit filed against MacroGenics, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: MGNX stocks, concerns whether certain MacroGenics directors are liable in connection with the allegations made in that lawsuit. The plaintiff alleges that, the defendants concealed material information and/or failed to disclose that the Company had conducted the progression-free survival ("PFS") and first interim overall survival ("OS") analyses for the SOPHIA trial by no later than October 10, 2018, that the October 2018 PFS analysis showed a 0.9 month improvement in PFS, and that the October 2018 OS interim analysis did not produce a statistically significant result and the interim OS Kaplan-Meier curves (a non-parametric statistic used to estimate the survival function from lifetime data) crossed in several spots (thereby violating the constant hazard assumption) and separated late.
   Week In Review: Week''s China Life Science Deals Total Over $2.5 Billion  2021/06/20 18:59:00 Seeking Alpha
   H.C. Wainwright Stick to Their Buy Rating for MacroGenics By Investing.com  2021/06/28 10:27:02 Investing.com
H.C. Wainwright Stick to Their Buy Rating for MacroGenics
   Zai Lab and Macrogenics partner in $1.5B cancer deal  2021/06/22 18:10:13 BioWorld
Zai Lab Ltd. and Macrogenics Inc. have announced a collaboration and license agreement involving up to four immuno-oncology molecules in a deal potentially worth upward of $1.5 billion. The deal makes sense as both are upcoming companies at around the same stage in development making progress in oncology with first products recently approved by regulators.
   NASDAQ:MGNX Long Term Investor Notice: Investigation of Potential Wrongdoing at MacroGenics, Inc.  2021/06/22 16:00:00 SBWire
An investigation on behalf of current long term investors in MacroGenics, Inc. (NASDAQ:MGNX) shares over possible breaches of fiduciary duty by certain officers and directors was announced. San Diego, CA -- ( SBWIRE ) -- 06/22/2021 -- Certain directors of MacroGenics, Inc. are under investigation concerning potential breaches of fiduciary duties. Investors who are current long term investors in MacroGenics, Inc. (NASDAQ: MGNX) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for investors in NASDAQ: MGNX stocks follows a lawsuit filed against MacroGenics, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: MGNX stocks, concerns whether certain MacroGenics directors are liable in connection with the allegations made in that lawsuit. The plaintiff alleges that, the defendants concealed material information and/or failed to disclose that the Company had conducted the progression-free survival ("PFS") and first interim overall survival ("OS") analyses for the SOPHIA trial by no later than October 10, 2018, that the October 2018 PFS analysis showed a 0.9 month improvement in PFS, and that the October 2018 OS interim analysis did not produce a statistically significant result and the interim OS Kaplan-Meier curves (a non-parametric statistic used to estimate the survival function from lifetime data) crossed in several spots (thereby violating the constant hazard assumption) and separated late.
   Week In Review: Week''s China Life Science Deals Total Over $2.5 Billion  2021/06/20 18:59:00 Seeking Alpha
   MacroGenics, Inc. Investors: Company Investigated by the Portnoy Law Firm  2021/06/17 18:49:00 Intrado Digital Media
Investors can contact the law firm at no cost to learn more about recovering their losses Investors can contact the law firm at no cost to learn more about recovering their losses
   The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx  2021/04/29 12:15:49 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28) Axonics, Inc. (NASDAQ: AXNX ) Boston Scientific Corporation (NYSE: BSX ) (reacted to first-quarter results) Celcuity Inc. (NASDAQ: CELC ) Celldex Therapeutics, Inc. (NASDAQ: CLDX) Galectin Therapeutics Inc. (NASDAQ: GALT ) Horizon Therapeutics Public Limited Company (NASDAQ: HZNP ) Insulet Corporation (NASDAQ: PODD ) Integra LifeSciences Holdings Corporation (NASDAQ: IART ) (announced first-quarter results) Lantheus Holdings, Inc. (NASDAQ: LNTH ) MacroGenics, Inc. (NASDAQ: MGNX ) NuVasive, Inc. (NASDAQ: NUVA) PRA Health Sciences, Inc. (NASDAQ: PRAH ) ShockWave Medical, Inc. (NASDAQ: SWAV ) Verastem, Inc. (NASDAQ: VSTM ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows April 28) Akoya Biosciences, Inc. (NASDAQ: AKYA ) Decibel Therapeutics, Inc. (NASDAQ: DBTX ) IRadimed Corporation (NASDAQ: IRMD ) Lucira Health, Inc. (NASDAQ: LHDX ) Mesoblast Limited (NASDAQ: MESO ) Protara Therapeutics, Inc. (NASDAQ: TARA ) PTC Therapeutics, Inc. (NASDAQ: PTCT ) Stocks In Focus Adverum Shares Sink On Serious Adverse Event Adverum Biotechnologies, Inc. (NASDAQ: ADVM ) announced a suspected unexpected serious adverse reaction of hypotony, which is clinically relevant decrease in ocular pressure, in its INFINITY clinical trial evaluating ADVM-022 gene therapy for the treatment of diabetic macular edema.
   MacroGenics Earnings and Growth Analysis : Stock market Insights & financial analysis  2021/02/25 00:14:00 Stock Market Daily
MacroGenics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   H.C. Wainwright Stick to Their Buy Rating for MacroGenics By Investing.com  2021/02/12 11:26:43 Investing.com
H.C. Wainwright Stick to Their Buy Rating for MacroGenics
   Thinking about buying stock in MacroGenics, Arbutus Biopharma, Riot Blockchain, Aclaris Therapeutics, or Myovant Sciences?  2020/12/17 14:31:00 PR Newswire
NEW YORK, Dec. 17, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MGNX, ABUS, RIOT, ACRS, and MYOV. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   The Week Ahead In Biotech: 2 IPOs Plus FDA Decisions On Moderna's COVID Vaccine And Drugs From Amgen, MacroGenics - Stocks News Feed  2020/12/13 14:14:30 Stocks News Feed
Biotech stocks advanced for a third straight week, defying the broader market weakness. The space got solid support from positive stock reactions to presentations made at hematology and breast cancer conferences. Positive vaccine news continued to flow. Pfizer Inc. (NYSE: PFE) and BioNTech SE – ADR (NASDAQ: BNTX) received the first regulatory nod for their mRNA… Read More »The Week Ahead In Biotech: 2 IPOs Plus FDA Decisions On Moderna’s COVID Vaccine And Drugs From Amgen, MacroGenics

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 マクロジェニクス MGNX MacroGenics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)